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Abstract
Background: Imputation is a statistical process used to predict genotypes of loci not directly assayed in a sample
of individuals. Our goal is to measure the performance of imputation in predicting the genotype of the best
known gene polymorphisms involved in drug metabolism using a common SNP array genotyping platform
generally exploited in genome wide association studies.
Methods: Thirty-nine (39) individuals were genotyped with both Affymetrix Genome Wide Human SNP 6.0 (AFFY)
and Affymetrix DMET Plus (DMET) platforms. AFFY and DMET contain nearly 900000 and 1931 markers respectively.
We used a 1000 Genomes Pilot + HapMap 3 reference panel. Imputation was performed using the computer
program Impute, version 2. SNPs contained in DMET, but not imputed, were analysed studying markers around
their chromosome regions. The efficacy of the imputation was measured evaluating the number of successfully
imputed SNPs (SSNPs).
Results: The imputation predicted the genotypes of 654 SNPs not present in the AFFY array, but contained in the
DMET array. Approximately 1000 SNPs were not annotated in the reference panel and therefore they could not be
directly imputed. After testing three different imputed genotype calling threshold (IGCT), we observed that
imputation performs at its best for IGCT value equal to 50%, with rate of SSNPs (MAF > 0.05) equal to 85%.
Conclusions: Most of the genes involved in drug metabolism can be imputed with high efficacy using standard
genome-wide genotyping platforms and imputing procedures.
Introduction
The therapeutic efficacy of any given drug is influenced by
a number of different variable factors including age,
weight, concurrent drug use and fixed parameters, such as
gender and genetic variation as well. Many of the enzymes
involved in drug metabolism are genetically polymorphic.
Consequently, their activity may differ depending upon an
individual’s genotype [1] and hence the genotype may
influence the success of individual treatment response. A
well-known example comes from the warfarin, that is an
effective commonly prescribed anticoagulant, for which a
variant in CYP4F2 gene (a drug metabolizing enzyme)
explained ~8% of dosing variability in several patient
populations [2].
Imputation can be used as a part of a genome-wide
association (GWA) studies or for a fine-mapping. In a gen-
ome-wide association study (GWAS) a dense set of single-
nucleotide polymorphisms (SNPs) across the genome is
genotyped to survey the most common genetic variation
for a role in disease or to identify the heritable quantitative
traits that are risk factors for disease [3] and often the
individuals studied undergo drug treatment. Moreover,
several, studies as in the case of our laboratory for Acute
Myeloid Leukemia (AML) patients, searched for factors
involved in the drug response at the genome level. The
first candidate genes are the ones that are already well
known [4] to be associated to the variability of drug
response. Therefore it would be useful to known whether
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the high density arrays used to scan the genome are able
to target these gene polymorphisms. Our goal is to mea-
sure the performance of imputation in predicting the gen-
otype of the untyped SNPs using two commercial SNPs
array platforms (The DMET™ Plus GeneChip array and
Genome Wide Human SNP 6.0 array). The two platforms
were developed with different intents: the first contains
known pharmacogenetic markers for drug metabolism




Blood samples from thirtynine patients with Acute Mye-
loid Leukemia (AML) were collected by professor Gio-
vanni Martinelli (Dep. of Hematology and Oncological
Sciences “L. and A. Seràgnoli” - University of Bologna).
Genomic DNA was extracted from peripheral blood sam-
ples with standard methods. A written informed consent
was collected from each individual and the study was
designed according to the ethical principles for medical
research involving human subjects stated by the World
Medical Association Declaration of Helsinki. The study
was also approved by the Department of Hematology and
Oncological Sciences “L. and A. Seràgnoli”. The indivi-
duals were genotyped with the following two platforms:
DMET™ Plus GeneChip array (DMET) and Genome
Wide Human SNP 6.0 array (AFFY, Affymetrix Inc,
Santa Clara, CA). A brief description follows.
Genotyping
DMET Plus
The DMET™ Plus GeneChip array (Affymetrix Inc,
Santa Clara, CA) contains 1931 SNPs and five Copy
Number Variants (CNVs) distributed on 225 drug meta-
bolizing enzymes and transporters genes. Amplified and
non-amplified DNA samples were combined for the
annealing and amplification steps, in which molecular
inversion probes (MIP) technology was exploited to gen-
otype all the genomic sites of interest in a single reaction.
DNA samples were subsequently purified, fragmented,
labeled and hybridized to the array to be scanned with
the Gene Chip Scanner 3000 (Affymetrix Inc, Santa
Clara, CA).
DMET Console version 1.1 (Affymetrix Inc, Santa
Clara, CA) was used to perform genotype calls using
standard parameters.
Affymetrix Genome Wide Human SNP 6.0
DNA samples were genotyped using the Genome Wide
Human SNP 6.0 array (Affymetrix Inc, Santa Clara, CA),
according to the manufacturer’s instructions and retriev-
ing genotype information for ~ 906,000 loci. Genomic
DNA samples were firstly digested with Nsp I and Sty I
restriction enzymes and then adaptor-ligated and PCR
amplified using a primer that recognizes the adaptor
sequence. PCR products were subsequently purified, frag-
mented, labeled, denatured and hybridized to oligonu-
cleotide probes attached to the surface of the array,
followed by washing and staining procedures, as well as
by scanning by means of the Gene Chip Scanner 3000
(Affymetrix Inc, Santa Clara, CA). Genotyping Console
3.0 package was used to perform genotype calls using
standard parameters.
SNPs in the study
The study was performed on 1860 of the 1931 markers
of DMET because 71 markers were discarded for the
following reasons:
• 13 markers have been coded in PharmGKB [4], but
have not been yet validated in dbsnp[5] and there-
fore they do not have an adequate coding to be
recognized in the reference panel, if present;
• 5 markers have two different annotated positions;
• 2 markers were duplicated;
• 5 markers presented 3 alleles in the study sample;
• 46 markers mapped on chromosome X (the soft-
ware IMPUTE 2 handles autosomal markers only).
Quality control
Before proceeding to the analysis, we performed some
quality control checks on the data. First, we tested the
concordance between the genetic and reported sex to
check for errors in labeling the samples. Second, all sub-
jects showing a genotype call rate < 95% would have
been removed. Third, SNPs mapping on the regions of
interest (i.e. containing the drug metabolism genes,
about 6000 SNPs) were removed when showing a
Hardy-Weinberg p-value inferior to 0.00001.
Categories of SNPs
The DMET SNPs investigated were grouped into 3
classes according to their presence in the AFFY platform
and in the reference panel, as follows:
• Shared: 205 markers present in both DMET and
AFFY arrays (genotyped matching is performed
between experimental genotypes).
• Reference Panel Only (RPO): 654 markers in
DMET and in the reference panel but not in AFFY
(genotyped matching is performed between DMET
experimental and AFFY imputed genotypes).
• Neither in AFFY nor in reference panel (NAR):
1001 markers in the DMET, but not in the AFFY or
in reference panel. Therefore, we did not perform
the imputation for this group of SNPs.
Regardless of the SNP classes (Shared, RPO and NAR),
markers were subdivided according to their minor allele
frequency (MAF). We used the following 7 ranges: 0,
0-0.05, 0.05-0.10, 0.1-0.2, 0.2-0.3, 0.3-0.4 and 0.4-0.5.
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Imputation
Imputation is a statistical process used to predict geno-
types that are not directly assayed in a sample of indivi-
duals. The term often refers to the situation in which a
reference panel of individuals genotyped at a dense set
of SNPs is used to impute into a study sample of indivi-
duals that have been genotyped at a subset of the SNPs
[3].
Imputation was performed using the method imple-
mented in the software IMPUTE 2 [6]. IMPUTE 2
returns the full probability distribution of the imputed
genotypes at each SNP for each individual. We gener-
ated discrete imputed genotypes by accepting a call if
the posterior probability for a genotype reached a pre-
specified threshold or set the genotype as missing other-
wise. Genotypes from AFFY here represent the study
sample and the reference panel used was prepared by
Marchini et al. [6] for the CEU population, including
information from the 1000 Genomes Pilot and HapMap
3 (release Jun 2010/Feb 2009) [7].
The imputation algorithm for large population genetic
datasets, built starting from a model developed by Li and
Stephens [8] to capture important features of the recombi-
nation process is based on Markov chain Monte Carlo
(MCMC) algorithm. Imputation typically involves a refer-
ence panel genotyped at a dense set of SNPs and a study
sample genotyped at a subset of these SNPs. We chose
this imputation method over the others because it allows
to use multiple reference panels. Imputation was per-
formed on the untyped markers of AFFY6.0 using the
CEU reference panel prepared by Marchini et al. [6], and
freely downloadable.
To speed up the procedure and to reduce the computa-
tion load imputation was performed subdividing the chro-
mosomal regions to be imputed in partially overlapping
2Mb-chunks that have been processed independently.
We defined following parameters in order to evaluate
the results of the imputation:
• Discordance: the proportion of genotype calls for
which the imputed genotype did not match the experi-
mental genotype call, averaged over all SNPs.
• Successful SNPs (SSNPs): in which the imputed gen-
otype matched the experimental genotype for at least
37 of 39 subjects (that roughly corresponds to 5% of
genotype error rate).
• Genotype error rate: proportion of unmatched gen-
otypes over the total genotypes.
The discordance was evaluated at three different
imputed genotype calling threshold (IGCT) of value. An
imputed genotype was called if the corresponding poster-
ior probability estimated by the imputation software
(IMPUTE 2) was higher than investigated IGCT. Imputed
genotypes below the IGCT were set as no-calls (i.e. miss-




Thirty-nine (39) individuals have been genotyped with
both DMET and AFFY array. Imputation was performed
on the untyped markers of AFFY (study sample), as
described in Materials and Methods.
DMET markers
Table 1 reports the distribution of the investigated
DMET SNPs according to their observed MAF, as well
as to Shared, RPO and NAR classes.
Shared SNPs
For 7995 genotypes (205 SNPs × 39 individuals), we
observed 59 no-calls for DMET and 164 for AFFY for a
corresponding genotype missing rate of 0.7% and 2%,
respectively, and seventy-nine (79) discordant genotypes,
corresponding to a mismatch rate of approximately
0.98%. Mismatches were randomly distributed among 40
different SNPs.
RPO SNPs
Six-hundred and fifty-four (654) SNPs were imputed
because present in the reference panel, but not in AFFY.
Three different IGCT were used: 50%, 70% and 90%.
Table 2 reports the overall discordance, genotype error
and no-call rate for each IGCT, according to MAF
values. Moreover, the number of SSNPs are shown. The
largest number of SSNPs was observed for IGCT of
50%, at any MAF range.
Table 1 DMET SNP distribution
MAF Shared RPO NAR
0 36 107 952
0-0.05 29 124 31
0.05-0.10 27 77 4
0.1-0.2 29 98 5
0.2-0.3 26 97 3
0.3-0.4 25 72 2
0.4-0.5 33 79 4
tot 205 654 1001
Shared: markers genotyped by both DMET and AFFY
RPO (Reference Panel Only): Number of markers that are present in DMET but
not in AFFY
NAR (Neither in AFFY nor in Reference Panel): Number of markers not
contained in reference panel so these SNPs cannot be directly imputed
For instance, 36 out of 205 shared SNPs, 107 out of 654 RPO SNPs and 952
out of 1001 NAR SNPs resulted to be monomorphic in the sample of 39
individual studied
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Discussion
The goal of the study is to measure the performance of
imputation when predicting the genotype of SNPs
involved in drug metabolism using a common SNP
array genotyping platform generally used for genome
wide association studies. High density SNP arrays have
been projected to tag the most common SNPs along the
genome. About 7 of the nearly 30 millions known SNPs
have a MAF > 0.05 and only 1 million is actually con-
tained in the standard SNP arrays. SNPs contained in
the arrays were generally chosen with idea to select the
minimum number of SNPs able to target the most com-
mon SNPs, exploiting the degree of linkage disequili-
brium among them. Thus, SNPs in the array do not
necessary belong to any class of genetic variants asso-
ciated with a particular function or with the variability
of any trait.
Pharmacogenetics and pharmacogenomics are inter-
ested in the study of genetic variations that are asso-
ciated with variable response to drugs in terms of
therapeutic effect, as well as adverse effects. In oncology,
for example, researchers are interested to study muta-
tions affecting genes coding for liver enzymes responsi-
ble for drug metabolism and mutations in tumoral DNA
leading to alteration in drug response. We investigated
how a high density SNPs array combined with imputa-
tion methods might help in studying a large number of
genetic polymorphisms involved in the drug metabolism.
To do that 39 individuals with AML were genotyped
with 2 different SNP arrays: the higly dense SNP AFFY
with about 1 million SNPs and the DMET array con-
taining the most known SNPs involved in the drug
metabolism. Thereafter, we checked how many SNPs
were in common between the 2 arrays and the number
of SNPs whose genotypes could be directly imputed
from AFFY to be then matched with the DMET experi-
mental genotypes.
A satisfactory match between experimental and
imputed genotypes of a given SNP means that imputa-
tion was good enough to substitute the real genotyping
for that SNPs. We measured the match between experi-
mental and imputed genotypes looking at the overall
concordance for a set of SNPs and the efficacy of impu-
tation for any single SNP.
Imputation was performed using reference panels
from HapMap 3 and the novel 1000 Genomes project.
We studied the genotypes of 1860 autosomal genetic
variations of the DMET array. The 39 individuals
resulted to be homozygotes for the most common allele
for 1095 markers. Moreover 184 markers showed a
MAF < 0.05. These large numbers of genetic variations
at a low MAF was expected according to the MAF indi-
cated by the manufacturer of the array and due to the
fact that the DMET was projected to contain the genetic
polymorphim involved in the drug metabolism, includ-
ing rare variants (someone associated with strong or
adverse drug reactions). For SNPs with low MAF we
could not measure with certainty the efficacy of imputa-
tion because of the low number of observations. A large
part of the DMET SNPs was not neither in the AFFY
nor in the reference panel used for imputation. Most of
them (983/1001) presented a MAF < 0.05 (952 showed
a MAF = 0). The low MAF explains why they were not
present in the reference panel or in the AFFY array.
With the advance of the 1000 Genomes project it is
likely that they will be included in the newly updated
reference panels and that imputation might become
accurate also for SNPs at a very low MAF.
Table 2 Imputation on RPO SNPs
IGCT 50% IGCT 70% IGCT 90%
discordance No-call N. of SSNPs discordance No-call N. of SSNPs discordance No-call N. of SSNPs
MAF #SNP
0 107 3,38% 0,00% 97 2,90% 1,13% 92 2,49% 2,47% 89
0-0.05 124 3,29% 0,02% 103 2,75% 1,55% 95 2,23% 4,07% 79
0.05-0.10 77 4,46% 0,13% 59 2,93% 3,06% 55 1,83% 8,09% 45
0.1-0.2 98 4,47% 0,31% 75 3,27% 3,43% 68 2,20% 9,37% 56
0.2-0.3 97 7,27% 1,11% 66 4,39% 7,43% 61 2,17% 15,25% 42
0.3-0.4 72 6,77% 1,07% 53 3,88% 7,26% 46 2,21% 14,10% 37
0.4-0.5 79 4,41% 0,26% 63 2,92% 3,60% 59 1,95% 9,22% 47
MAF: Minor Allele Frequency
#SNP: Number of SNPs
IGCT: imputed genotype calling threshold
Discordance: the proportion of genotype calls for which the imputed genotype did not match the experimental genotype call, averaged over all SNPs.
No-call: proportion of genotypes whose posterior probability did not reach a pre-specified IGCT
For instance, the first row reports the results of 107 SNPs having a MAF = 0 in the study sample for IGCT = 50%: the discordance is 3.38% and the no-call rate is
0.00%. For the IGCT = 90%, the discordance and no-call are 2.49% and 2.47%, respectively.
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AFFY and DMET arrays share 205 SNPs. The genotype
missing calls for DMET and AFFY were 59 (~0.7%) and
164 (~2%) respectively, indicating a higher sensibility of
the DMET array. Moreover, 79 genotypes were discordant
(~1%). Due to the fact that both experimentally deter-
mined and imputed genotypes are called with some degree
of error, we cannot know which call (if either) is correct,
so we report concordance rather than accuracy. We
looked if imputation may help in detecting the array in
which the genotype was badly called by selecting 2 SNPs,
rs2108622 (2 mismatches) and rs1060463 (1 mismatch),
presenting genotype mismatches. The genotypes were
imputed after masking them in the AFFY array. Imputa-
tion suggests that the 2 rs2108622 heterozygotes called by
the DMET array were 2 homozygotes as indicated by the
AFFY array. On the other hand imputation and DMET
were concordant to call rs1060463 homozygote in contrast
with the AFFY call indicating a heterozygote (data not
shown). This would suggest that the genotype calling is
not totally accurate for both the arrays, as expected for the
AFFY. However, since imputation suffers from a degree of
uncertainty, we should perform the genotyping with an
independent method to estimate the error rate of the 2
platforms and confirm the efficacy of imputation in these
cases.
Other 654 SNPs present in DMET, but not in AFFY
6.0, were imputed. The MAF observed for 107 SNPs was
0 and additional 124 SNPs showed a MAF < 0.05 (see
Table 2). Of the remaining 373 imputed SNPs 316 (85%),
289 (77%) or 227 (60%) SNPs, according to the increasing
value of the 3 IGCTs, resulted to be successful SNPs with
an overall concordance ranging from 92.6% to 98%. It is
noteworthy that the “no call” rate was higher for markers
having a MAF between 0.2 and 0.4 at each of the 3
IGCTs indicating that uncertainty linked to genotype
calls for these SNPs is higher than for the others.
We should note that in the present paper we used a
CEU reference panel including a large number of SNPs
and this represents a key factor for a reliable imputation.
It could be argued that the accuracy of imputation also
depends on the degree of LD among SNPs of the investi-
gated region and therefore that imputation accuracy
would be lower in region presenting a low LD among
SNPs. However Rosenberg et al. [9] showed that imputa-
tion accuracy, when based on an external reference (as in
our case study), is not correlated with LD patterns of the
imputed region, but depends largely on the genetic com-
position (i.e. population descent) of the reference panel
used. This suggests that the accuracy of imputation might
be improved when using the most suitable reference panel
according to the sample of individuals studied.
Imputation resulted to be a reliable method to predict
and study genotype of SNPs associated to drug metabo-
lism when individuals were genotyped with many SNPs
genome wide. In a recent study we described 2 genetic
variants (rs6811453 and rs1826909) of the ADH1A gene
associated to drug response in AML patients [10]. These
2 genetic variants have been imputed with a concor-
dance of 100% (39/39 individuals for both SNPs) and
therefore we would have been able to detected the asso-
ciation between the genetic markers and drug response
also using the imputed genotypes, thus corroborating
the efficacy of imputation for those SNPs.
Conclusion
This study indicates that imputation is a valid method,
however it strongly depends on the array used for geno-
typing (that is on SNPs present in the array; different
arrays have different SNPs) and on the reference panel
used. Future studies will investigate how more and more
detailed reference panels impact on the efficacy of impu-
tation, with particular attention on SNPs with rare
alleles.
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